Literature DB >> 8566020

Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells.

J Plumas1, L Chaperot, M C Jacob, J P Molens, C Giroux, J J Sotto, J C Bensa.   

Abstract

We analyzed the stimulating capacities of malignant B cells from non-Hodgkin's lymphomas (NHL) to induce an allogeneic response in primary mixed lymphocyte reaction (MLR). T cells purified from a single healthy donor (KS) were used to compare the responses induced by either malignant or hyperplastic cells. Malignant B cells induced strong proliferation of KS cells independently of their level of expression of adhesion molecules. The KS cells after MLR were predominantly CD3+, CD25+, HLA-DR+, Ki67+ and CD45RO+ T cells, and the CD4/CD8 ratio was heterogeneous (from 0.8 to 2.7). To investigate the role of co-stimulatory molecules CD80 and CD86 for the stimulatory capacities of B cells, the expression of both molecules was analyzed before and during the MLR. Most fresh malignant B cells were negative for CD80 and CD86, whereas co-cultured B cells expressed high levels of both molecules. This expression was crucial for T cell proliferation, since monoclonal antibodies directed against CD80 and CD86 completely abrogated the MLR. We also report that KS responding cells at the end of co-culture were able to lyse fresh B cells used as stimulator cells to different extents (from 10 to 51%), and the level of lysis was enhanced after PMA activation of the target cells. Inhibition experiments using CD8 and CD4 mAb showed that effector cells were mainly CD8+. This report is the first to describe the accessory function of human malignant B cells from NHL and their sensitivity to lysis mediated by CD8+ T cells, and suggests new strategies for the development of antitumor immunity in NHL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8566020     DOI: 10.1002/eji.1830251220

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.

Authors:  Pedro Horna; Alex Cuenca; Fengdong Cheng; Jason Brayer; Hong-Wei Wang; Ivan Borrello; Hyam Levitsky; Eduardo M Sotomayor
Journal:  Blood       Date:  2005-12-08       Impact factor: 22.113

Review 2.  Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.

Authors:  Michelle A Fanale; Anas Younes
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

Review 4.  Target Therapy in Hematological Malignances: New Monoclonal Antibodies.

Authors:  Monika Podhorecka; Justyna Markowicz; Agnieszka Szymczyk; Johannes Pawlowski
Journal:  Int Sch Res Notices       Date:  2014-10-29

Review 5.  PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.

Authors:  Zijun Y Xu-Monette; Jianfeng Zhou; Ken H Young
Journal:  Blood       Date:  2017-11-08       Impact factor: 25.476

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.